AUD10.40
0.29% today
Australia, Sep 03, 08:10 am CET
ISIN
AU000000CUV3
Symbol
CUV

Clinuvel Pharmaceutical Target price 2025 - Analyst rating & recommendation

Clinuvel Pharmaceutical Classifications & Recommendation:

Buy
90%
Hold
10%

Clinuvel Pharmaceutical Price Target

Target Price AUD23.54
Price AUD10.40
Potential
Number of Estimates 7
7 Analysts have issued a price target Clinuvel Pharmaceutical 2026 . The average Clinuvel Pharmaceutical target price is AUD23.54. This is higher than the current stock price. The highest price target is
AUD42.00 303.85%
register free of charge
, the lowest is .
A rating was issued by 10 analysts: 9 Analysts recommend Clinuvel Pharmaceutical to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Clinuvel Pharmaceutical stock has an average upside potential 2026 of . Most analysts recommend the Clinuvel Pharmaceutical stock at Purchase.

Sales and Margin forecast 2026, 2027 to 2032

Create a premium account to unlock analyst estimates. Learn more

Jun '25 2026
Estimates
Revenue Million AUD 95.02 108.58
0.50% 14.27%
EBITDA Margin 49.37% 47.75%
16.51% 3.28%
Net Margin 38.07% 37.71%
2.00% 0.93%

8 Analysts have issued a sales forecast Clinuvel Pharmaceutical 2026 . The average Clinuvel Pharmaceutical sales estimate is

AUD109m
Unlock
. This is
14.27% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
AUD123m 29.29%
Unlock
, the lowest is
AUD101m 6.34%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2025 AUD95.0m 0.50%
2026
AUD109m 14.27%
Unlock
2027
AUD118m 8.84%
Unlock
2028
AUD180m 52.21%
Unlock
2029
AUD356m 98.10%
Unlock
2030
AUD140m 60.83%
Unlock
2031
AUD177m 27.12%
Unlock
2032
AUD194m 9.15%
Unlock

7 Analysts have issued an Clinuvel Pharmaceutical EBITDA forecast 2026. The average Clinuvel Pharmaceutical EBITDA estimate is

AUD51.8m
Unlock
. This is
10.52% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
AUD64.1m 36.54%
Unlock
, the lowest is
AUD40.2m 14.20%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2025 AUD46.9m 16.93%
2026
AUD51.8m 10.52%
Unlock
2027
AUD60.0m 15.79%
Unlock
2028
AUD96.8m 61.27%
Unlock
2029
AUD74.3m 23.30%
Unlock
2030
AUD79.3m 6.81%
Unlock
2031
AUD86.8m 9.44%
Unlock
2032
AUD95.9m 10.49%
Unlock

EBITDA Margin

2025 49.37% 16.51%
2026
47.75% 3.28%
Unlock
2027
50.80% 6.39%
Unlock
2028
53.82% 5.94%
Unlock
2029
20.84% 61.28%
Unlock
2030
56.82% 172.65%
Unlock
2031
48.92% 13.90%
Unlock
2032
49.52% 1.23%
Unlock

8 Clinuvel Pharmaceutical Analysts have issued a net profit forecast 2026. The average Clinuvel Pharmaceutical net profit estimate is

AUD41.0m
Unlock
. This is
13.22% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
AUD51.0m 40.97%
Unlock
, the lowest is
AUD35.1m 2.90%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2025 AUD36.2m 1.49%
2026
AUD41.0m 13.22%
Unlock
2027
AUD47.3m 15.56%
Unlock
2028
AUD74.8m 58.05%
Unlock
2029
AUD56.8m 24.07%
Unlock
2030
AUD61.4m 8.05%
Unlock
2031
AUD67.4m 9.91%
Unlock
2032
AUD74.5m 10.53%
Unlock

Net Margin

2025 38.07% 2.00%
2026
37.71% 0.93%
Unlock
2027
40.04% 6.18%
Unlock
2028
41.58% 3.85%
Unlock
2029
15.94% 61.66%
Unlock
2030
43.96% 175.78%
Unlock
2031
38.01% 13.54%
Unlock
2032
38.49% 1.26%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2032

Create a premium account to unlock analyst estimates. Learn more

Jun '25 2026
Estimates
Earnings Per Share AUD 0.72 0.82
2.86% 13.89%
P/E 12.77
EV/Sales 2.89

8 Analysts have issued a Clinuvel Pharmaceutical forecast for earnings per share. The average Clinuvel Pharmaceutical EPS is

AUD0.82
Unlock
. This is
13.89% higher
Unlock
than earnings per share in the financial year 2025. The highest EPS forecast is
AUD1.02 41.67%
Unlock
, the lowest is
AUD0.70 2.78%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 AUD0.72 2.86%
2026
AUD0.82 13.89%
Unlock
2027
AUD0.94 14.63%
Unlock
2028
AUD1.49 58.51%
Unlock
2029
AUD1.13 24.16%
Unlock
2030
AUD1.22 7.96%
Unlock
2031
AUD1.35 10.66%
Unlock
2032
AUD1.49 10.37%
Unlock

P/E ratio

Current 14.49 35.16%
2026
12.77 11.85%
Unlock
2027
11.05 13.47%
Unlock
2028
6.99 36.74%
Unlock
2029
9.20 31.62%
Unlock
2030
8.52 7.39%
Unlock
2031
7.75 9.04%
Unlock
2032
7.01 9.55%
Unlock

Based on analysts' sales estimates for 2026, the Clinuvel Pharmaceutical stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 3.30 47.70%
2026
2.89 12.44%
Unlock
2027
2.65 8.13%
Unlock
2028
1.74 34.30%
Unlock
2029
0.88 49.52%
Unlock
2030
2.25 155.28%
Unlock
2031
1.77 21.33%
Unlock
2032
1.62 8.38%
Unlock

P/S ratio

Current 5.65 31.27%
2026
4.95 12.49%
Unlock
2027
4.55 8.12%
Unlock
2028
2.99 34.30%
Unlock
2029
1.51 49.52%
Unlock
2030
3.85 155.28%
Unlock
2031
3.03 21.33%
Unlock
2032
2.77 8.38%
Unlock

Current Clinuvel Pharmaceutical Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
WILSONS
Locked
Locked
Locked Jul 17 2025
JEFFERIES
Locked
Locked
Locked Jul 16 2025
BELL POTTER SECURITIES
Locked
Locked
Locked Jul 02 2025
MOELIS AUSTRALIA SECURITIES
Locked
Locked
Locked Apr 09 2025
WILSONS
Locked
Locked
Locked Apr 07 2025
BELL POTTER SECURITIES
Locked
Locked
Locked Mar 25 2025
JEFFERIES
Locked
Locked
Locked Mar 05 2025
Analyst Rating Date
Locked
WILSONS:
Locked
Locked
Jul 17 2025
Locked
JEFFERIES:
Locked
Locked
Jul 16 2025
Locked
BELL POTTER SECURITIES:
Locked
Locked
Jul 02 2025
Locked
MOELIS AUSTRALIA SECURITIES:
Locked
Locked
Apr 09 2025
Locked
WILSONS:
Locked
Locked
Apr 07 2025
Locked
BELL POTTER SECURITIES:
Locked
Locked
Mar 25 2025
Locked
JEFFERIES:
Locked
Locked
Mar 05 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today